Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Soligenix (SNGX), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, has announced that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised its option to advance preclinical development of OrbeShieldTM (oral beclomethasone 17,21-dipropionate or oral BDP).
Subscribe to our email newsletter
The 12-month option provides an additional $2.1 million to Soligenix to advance OrbeShield as a medical countermeasure (MCM) for the treatment of gastrointestinal acute radiation syndrome (GI ARS). NIAID granted an initial award of $2.1 million to Soligenix on September 18, 2013. The total contract award is valued at up to $6.4 million over three years.
Soligenix’s GI ARS program is supported by contract awards from both the Biomedical Advanced Research Development Authority (BARDA) and NIAID, totaling up to approximately $32 million.
In addition to developing oral BDP as a MCM, the company is also pursuing oral BDP as a treatment for GI inflammation in pediatric Crohn’s disease, acute radiation enteritis and chronic Graft-versus-Host disease (cGVHD).
"The execution of the first option reflects NIAID’s ongoing commitment to developing MCMs for GI ARS and the compelling nature of Soligenix’s OrbeShield product," stated Christopher J. Schaber, PhD, President & Chief Executive Officer of Soligenix.
"This continued funding, plus the BARDA contract awarded last year, has the potential to provide the necessary funding to advance the development of OrbeShield while building upon the scientific evidence supporting its use as a potential MCM in GI ARS. We thank NIAID for their past and present support and look forward to continuing our close collaboration as we advance this technology."
ARS occurs after toxic radiation exposure and involves several organ systems, notably the bone marrow, the GI tract and later the lungs. In the event of a nuclear disaster or terrorist detonation of a nuclear bomb, people exposed to radiation levels greater than 2 Gy are at high risk of developing ARS. Exposure to high doses of radiation exceeding 10 to 12 Gy causes acute GI injury, which can result in death in 5 to 15 days.
The GI tract is highly sensitive due to the requirement for incessant proliferation of crypt stem cells and production of mucosal epithelium. The extent of injury to the bone marrow and the GI tract are the principal determinants of survival after exposure to total body irradiation. Although hematopoietic ARS can be rescued by bone marrow transplantation or growth factor administration, there is no established treatment or preventive measure for the GI damage that occurs after high-dose radiation.
Therefore, there is an urgent need to develop specific MCMs against the lethal consequences of radiation-induced GI injury.
OrbeShield is formulated for oral administration in GI ARS patients as a single product consisting of two tablets; one tablet releases BDP in the proximal portions of the GI tract and the other tablet releases BDP in the distal portions of the GI tract.
BDP has been marketed in the US and worldwide since the early 1970s as the active pharmaceutical ingredient in inhalation products for the treatment of allergic rhinitis and asthma. To date, oral BDP has been safely administered to more than 350 human subjects in multiple clinical studies.
Oral BDP is also being developed for use in other GI disorders characterized by severe inflammation such as pediatric Crohn’s disease, radiation enteritis and cGVHD.